Sami-Sabinsa, the multi-national health science company founded 35 years ago by Dr. Muhammed Majeed, announces that Curcumin C3 Reduct® has been approved by the National Health Surveillance Agency in Brazil for inclusion on ANVISA’s IN28 list. This approval allows introduction and commercialization of C3 Reduct®, most active metabolite of curcumin, in food and supplements in Brazil. Approval is based on a dossier submitted to ANVISA detailing safety and efficacy of a product. C3 Reduct® is the only Tetrahydrocurcuminoids approved in this market. C3 Reduct® was given approval at dosage of 120mg/day.

Curcumin C3 Reduct®, Sami-Sabinsa’s patented and clinically safe 95% tetrahydrocurcuminoids, is the result of the company’s research into metabolites of curcuminoids that have unraveled the role of tetrahydrocurcuminoids as not only the major metabolites but also pharmacologically superior to curcuminoids themselves. It is not the curcumin, but its metabolite, tetrahydrocurcumin (THC), which is responsible for its biological function in the body.

curcumin-c3-reduct

Curcumin C3 Reduct®, tetrahydrocurcuminoids (THCs), the cascading antioxidants and the major metabolites of Curcuminoids, are the colorless hydrogenated compounds derived from Sami-Sabinsa’s Curcumin C3 Complex® curcuminoids: curcumin, demethoxycurcumin and bisdemethoxycurcumin, of which curcumin is the main phenolic compound. As a cascading antioxidant, in comparison to a standalone antioxidant, Curcumin C3 Reduct® will act as an antioxidant for a longer time and show cumulatively stronger activity. With higher bioavailability in the gut compared to parent curcuminoids, Curcumin C3 Reduct® can be delivered in a smaller tablet or capsule.

Sami-Sabinsa VP Scientific Affairs Dr. Anurag Pande, who spearheaded the team for submission to ANVISA, said “Many congratulations to our Sami-Sabinsa Brazil team for their first approval. This approval of C3 Reduct® marks a significant milestone in the supplement market in Brazil, ushering in the era of Next-Generation of Curcuminoids.”

“Approval of C3 Reduct® by ANVISA on the IN28 list is a testament to the science that Sami-Sabinsa has created on Curcumin metabolites,” remarked Dr. Majeed. “This is our first approval in the Brazilian market, with more to follow.”

Sami-Sabinsa holds patents on Curcumin C3 Reduct® in multiple other countries throughout the world.